We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

AGILENT

  Silver Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Metabolomics Profiles Associated with Diabetic Retinopathy

By LabMedica International staff writers
Posted on 16 Nov 2020
Print article
Image: The AbsoluteIDQ p180 kit provides scientists with highly reproducible metabolomics data to confidently obtain detailed knowledge about the metabolic phenotypes in their studies (Photo courtesy of BIOCRATES Life Sciences).
Image: The AbsoluteIDQ p180 kit provides scientists with highly reproducible metabolomics data to confidently obtain detailed knowledge about the metabolic phenotypes in their studies (Photo courtesy of BIOCRATES Life Sciences).
Diabetic retinopathy (DR), like diabetic neuropathy and nephropathy, is a common complication of diabetes. It is the leading cause of loss of vision in diabetic patients. Long-standing disease, along with hyperglycemia, hyperlipidemia, hypertension, and genetic factors, is a major risk factor of diabetes retinopathy.

Metabolomics profiling is a rapidly evolving method used to identify the metabolites in biological fluids and investigate disease progression. Quantitative analyses of small-molecule metabolites in biological specimens such as blood and urine can be performed due to the rapid advances in metabolomics.

Medical Scientists at the Chungbuk National University College of Medicine (Cheongju, Republic of Korea) included in a study 317 type 2 diabetes (T2D) patients of which 143 non-DR (NDR) patients, 123 non- proliferative DR (NPDR) patients, and 51 proliferative-DR (PDR) patients. Gender, age, height, weight, body mass index (BMI), and HbA1c, glucose, and creatinine levels of all patients were recorded.

The serum samples of the T2D patients were analyzed using a targeted metabolomics approach. To quantify the metabolites, liquid chromatography (LC) and flow-injection analysis (FIA)–mass spectrometry (MS) were performed using the AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). The serum samples were analyzed using the API 4000 QTRAP LC/MS/MS system (Applied Biosystems, Foster City, CA, USA) and the Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA, USA).

The investigators reported that the concentrations of 62 metabolites of the NDR versus DR group, 53 metabolites of the NDR versus NPDR group, and 30 metabolites of the NDR versus PDR group were found to be significantly different. Sixteen metabolites were selected as specific metabolites common to NPDR and PDR. Among them, three metabolites including total dimethylarginine, tryptophan, and kynurenine were potential makers of DR progression in T2D patients. Additionally, several metabolites such as carnitines, several amino acids, and phosphatidylcholines also showed a biomarker potential.

The authors concluded that they had revealed via comprehensive metabolomics profiling using a high-throughput platform, several metabolites associated with DR. These new DR-related metabolites should be considered in the study of the mechanism behind the initiation and progression of DR in T2D patients. The study was published on October 29, 2020 in the journal PLOS ONE.

Related Links:
Chungbuk National University College of Medicine
BIOCRATES Life Sciences
Applied Biosystems
Agilent Technologies



Gold Supplier
Digital Trichoscope
DE330T
New
Silver Supplier
COVID-19 NAb Test Solution
COVID-19 NAb Test Solution
New
Urea Breath Test System for H. Pylori
BreathID Hp Lab
New
Automated RNA Extraction & PCR Setup
Omnia LH 75 Pro

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.